Cosmetics & Personal Care | Monthly bulletin | December 2019
Regulatory news - Eurofins updates - Commercial news
Europe
Amending Annex V and VI of Cosmetics Regulation
On 7th November 2019, the European Commission published the following two amendments.
Recent SCCS publications on Cosmetics
Following some recent publications of the Scientific Committee on Consumer Safety (SCCS):
Preliminary opinion on cosmetic ingredients:
Final Opinion:
- SCCS - Final Opinion on hair dye Methylimidazoliumpropyl p-phenylenediamine HCl (A166)
- SCCS - Final Opinion on Hydroxypropyl p-phenylenediamine and its dihydrochloride salt (A165)
Guidances:
New mandates:
- SCCS - Request for a scientific Opinion on Platinum (nano) - Colloidal Platinum (nano) [CAS No 7440-06-4, EC No. 231-116-1] and Acetyl tetrapeptide-17 Colloidal Platinum (nano)
- SCCS - Request for a scientific Opinion on Gold (nano) - Colloidal Gold (nano) [CAS No 7440-57-5 / EC No. 231-165-9], Gold Thioethylamino Hyaluronic Acid (nano) [CAS No. 1360157-34-1/ EC No. not available] and Acetyl heptapeptide-9, Colloidal gold (nano)
Find below a summary table with recent regulation proposals notified to European Commission (Non-exhaustive):
|
Notification number |
Countries |
Title |
|
France |
Decree on intense pulsed light depilation processes for aesthetic purposes.
Its aims is to regulate the practice of intense pulsed light depilation in the context of aesthetic services provided by doctors, medical assistants or beauticians, particularly with regard to: |
Product Recalls / Alerts
Below you will find a monthly summary of product recalls and alerts in Europe (Source “RAPEX”) and in the US (Source “CPSC”).
RAPEX (European Commission Rapid Alert System for dangerous non-food products – Alerts reported by EU national authorities).
The following 15 alerts regarding Cosmetic & Personal Care products have been reported, from week 43 until week 46 of 2019.
|
Type of Risk |
Number of alerts |
Notes |
|
Chemical |
13 |
Temporary tattoo: It contains methylisothiazolinone (MI), which is not permitted in leave-on cosmetic products. |
|
Tattoo ink: contains the aromatic amines o-anisidine and o-toluidine and an excessive amount of polycyclic aromatic hydrocarbons (PAHs) and benzo[a]pyrene |
||
|
Toothpaste: It contains aminocaproic acid, which use is banned in cosmetic products. |
||
|
Skin lightening product: It contains hydroquinone |
||
|
Microbiological |
2 |
Hair dye: It contains excessive amount of aerobic mesophilic bacteria |
|
Shampoo/shower gel: It contains an excessive amount of aerobic mesophilic bacteria, including Pluralibacter gergoviae bacteria |
From 21st October to 20th November 2019, CPSC (Consumer Product Safety Commission) has published the following recalls: 1 recall regarding Cosmetic & Personal Care products.
|
Type of Risk |
Number of alerts |
Notes |
|
Poisoning risk |
1 |
Essential Oils: The product contains the substance methyl salicylate, which must be in child resistant packaging as required by the Poison Prevention Packaging Act (PPPA). |
Eurofins Cosmetics & Personal offers a full range of hair testing
Eurofins Cosmetics & Personal Care offers the latest testing facilities and techniques for determining the efficacy of hair care, supporting products claims and competitive benchmarking. With a growing number of laboratories dedicated to cosmetics, Eurofins group instrumental evaluation offer continues to grow.
A large range of tests on hair tresses is now available to evaluate claims for every type of hair products such as:
- hair coloration (colour protection and vibrancy, long-lasting effect)
- hair care products (fortifying effect, repair effect, moisturizing, nourishing, anti-pollution, volume effect, shine, anti-frizz, conditioning, UV/Thermal protection)
- hair styling products (hair curl retention)
This offer can be completed by a large range of clinical testing within our 15 clinical laboratories worldwide.
FDA Sunscreen Monograph Postponed
A proposed set of rules and regulations initiated by the U.S. Food and Drug Administration (FDA) concerning the safety and effectiveness of over-the-counter sunscreen products has been postponed, according to FDA officials. Initially brought into play by the Sunscreen Innovation Act of 2014, the proposed November 26th, 2019 deadline was not achievable. With more than 20,000 comments still needing to be addressed, the FDA has made it a priority to sift through all concerns brought up by industry advocates and supplying companies.
These new policies were proposed to ensure OTC sunscreens that do not have FDA-approved claims do not harm or prove ineffective for customers. Under these new guidelines, special requirements would be required for these products to reach shelves. Active ingredient safety checks, dosage forms, labeling requirements, and SPF values are a few of these provisions, along with mandatory monographs that would provide sufficient data to approve OTC sunscreens for public use. Final formulation testing and recordkeeping would also be assessed and include minimum time periods during which records could be kept.
With the proposed rule set being adjusted to accommodate the large number of comments and questions brought up by concerned parties, the revised deadline does not have a set date at this time.
Eurofins Clinical Lab in Guangzhou is now ISO 9001:2015 Certified
Join us in celebrating our new ISO 9001:2015 Certificate! Eurofins Clinical Lab in Guangzhou is successfully certified.
Our colleagues in the lab worked with great effort and team spirit to reach this important milestone in our drive for excellence in both lab quality and lab governance.
Eurofins Cosmetics & Personal Care's top priority is to ensure our businesses are satisfying our customers' needs by providing products and services that meet client and regulatory requirements. With the ISO 9001:2015 certification we will be held to higher standards and this increased focus on quality management will continue to benefit our business.
Clinical Study Do's and Don'ts: Designing Safety & Claim Support Studies by Michael Anthonavage
Michael Anthonavage has written a blog for the New York Society of Cosmetic Chemists (NYSCC) about the Do's and Don'ts of clinical testing. You will find in the article some do's and don'ts that he has been faced with, both as client and as a provider of clinical testing for personal care and cosmetic products. Michael is the current VP of Operations and Technology at Eurofins CRL, he's specializes in R&D to marketing translation and claim validation, both in vitro and in vivo.
